Role and Safety of Tirofiban in Peri-Interventional Antiplatelet Management for Aneurysm Treatment.

Abstract

Background: Tirofiban is administered for the treatment of aneurysms in cases of thromboembolic complications, as well as in cases of acute stenting or flow-diverter implantation required within the scope of aneurysm treatment. We aimed to investigate the efficacy and safety of tirofiban in this group of patients.

Methods: We conducted a retrospective analysis of all patients undergoing aneurysm treatment and receiving peri-interventional tirofiban administration at our institution between 2009 and 2019.

Results: A total of 105 patients were included, with 61% women and 39% men (mean age = 53 years, IQR: 44-60 years). Sixty-seven patients underwent emergency aneurysm treatment, and thirty-eight were treated electively. Hemorrhagic events occurred in 22% (15/67) of the patients treated acutely, with 7.46% (5/67) exhibiting symptoms. Patients undergoing elective aneurysm treatment experienced no hemorrhagic events (p = 0.002). Among the 35 patients who required an external ventricular drain (EVD), 22.86% (8/35) developed EVD-related hemorrhages; however, none were symptomatic (p = 0.007). Of the five patients who required a craniotomy, two experienced significant bleeding, and one experienced non-significant craniotomy-related bleeding (p = 0.20).

Conclusion: Tirofiban may be safe for use during peri-interventional complications or emergency stenting in aneurysm treatment. However, caution is necessary when craniotomy is required. In elective aneurysm treatments, administering Tirofiban in response to periprocedural complications appears to be safe.